London Stock Exchange welcomes Trellus Health plc to AIM

London Stock Exchange today welcomes Trellus Health plc (“Trellus” or the “Company”), a leading resilience-driven connected health solution for chronic conditions, to celebrate the listing of the Company's public shares onto AIM, under the ticker "TRLS". The Company is incorporated in England and Wales with US headquarters in White Plains, NY.

Trellus Health is commercialising the provision of digital chronic condition management solutions for health plans and employers that utilise the scientifically validated Gaining Resilience Through Transitions (GRITT™) methodology and a proprietary HIPAA compliant technology platform called TrellusElevate™, to coordinate and deliver personalised care remotely via telemedicine. 

The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85% reduction in emergency department visits and hospitalisations. The Company is initially focused on Inflammatory Bowel Diseases (“IBD”), which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but also considers its approach to have potential utility and demand across many chronic conditions.

Trellus received a USD5 million Seed investment from London-listed EKF Diagnostics Holdings PLC in August 2020, in partnership with the Icahn School of Medicine at Mount Sinai (“ISMMS”). In conjunction with the Seed financing, Trellus secured the exclusive worldwide license from ISMMS to commercialise the patent-pending GRITT™ methodology for IBD and seven chronic conditions including diabetes, kidney disease, cardiovascular disease, auto-immune conditions, and cancer. Additionally, the company has successfully raised £28.5 million in total on 20 May 2021, which includes the gross proceeds of £27.6 million from the placing and subscription, plus £0.9 million from the Restricted Offer. The company’s market capitalisation is approximately £64.6 million on admission, and all 2,250,000 Ordinary Shares available under the Restricted Offer were issued.

Monique Fayad, Chief Executive Officer of Trellus Health, said: “I would like to thank our dedicated colleagues, advisors, investors and shareholders, who made this transaction happen. We are incredibly proud to have reached this important milestone, as our AIM IPO will enable us to scale our business and technology platform in the US and abroad. 

I look forward to Trellus Health continuing to provide valuable solutions by using the GRITT™ methodology and our resilience-driven multidisciplinary care model, to leverage expert whole-person care, data science and technology to deliver personalised and more cost-effective care for all people living with chronic conditions.”

Dr. Marla Dubinsky, Co-Founder and Non-Executive Board Director of Trellus Health, said: “After experiencing the significant positive outcomes of the GRITT™ methodology at our leading academic medical centre, we are delighted that Trellus Health’s AIM financing will enable the company to scale this validated approach and multidisciplinary care model to all people living with IBD, regardless of their geographic location.  

The COVID-19 pandemic heightened global awareness of the importance of resilience and connectivity to address the physical and emotional needs of all people, not only those living with chronic conditions. Over the last year, clinicians and patients have grown accustomed to the convenience and efficiency of digital health and telemedicine interactions, which will have a lasting impact on the delivery and coordination of whole-person care for patients living with complex chronic conditions. Trellus Health’s AIM financing will further allow us to meet patients where they are, while remotely monitoring them for rising risk indicators to predict and prevent costly unplanned and inappropriate care.”

To find out more about Trellus Health PLC, please visit: 

Strictly Come Dancing/Dancing with the Stars celebrity, Amy Dowden, recently revealed her lifelong battle with Crohn’s disease and has agreed to become an ambassador for Trellus Health (official announcement to be made in due course). In the meantime, you can see her video testimonial here:

Quick facts

Market: AIM
Instrument market cap (£m)
Listing/Admission to trading
28 May 2021
Looking for new and recent issues?

More recent

London Stock Exchange welcomes Graft Polymer Plc to the Main Market

The London Stock Exchange today welcomes Graft Polymer (UK) PLC, a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, to the Main Market, trading under the ticker symbol “GPL”.

Graft Polymer is an early-stage company with a state-of-the-art polymer research and development, manufa

Learn more
London Stock Exchange welcomes Genflow Biosciences Plc to the Main Market

London Stock Exchange today welcomes Genflow Biosciences Plc, a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, to the Standard Listing Segment of the Main Market, under the ticker symbol "GENF".

Genflow Biosciences opened th

Learn more
London Stock Exchange welcomes East Star Resources Plc and their readmission to the Main Market

London Stock Exchange welcomes the readmission of East Star Resources, a company focused on the discovery and development of gold, copper, and base metals in Kazakhstan, to the Main Market under the ticker “EST”. The company raised gross proceeds of £3.1 million via a placing and subscription of 62,000,000 shares at £0.05 per share, delivering a ma

Learn more
London Stock Exchange celebrates FTSE Russell’s index partnership with Abu Dhabi Securities Exchange

Today, London Stock Exchange markets were opened by Abu Dhabi Securities Exchange and FTSE Russell to mark their partnership and the launch of the FTSE ADX Index Series.

FTSE ADX General Index FTSE ADX Sector Indexes FTSE Russell provides daily index calculations on the ADX General Index FTSE ADX General Index replaces the ADX General Index FTSE Russ

Learn more